Scarica l'app Stockscreener
0.775
14.81%
0.10
Pre-mercato:
.78
0.005
+0.65%
Precedente Chiudi:
$0.675
Aprire:
$0.681
Volume 24 ore:
354.31K
Relative Volume:
1.43
Capitalizzazione di mercato:
$80.59M
Reddito:
$1.29M
Utile/perdita netta:
$-29.87M
Rapporto P/E:
-2.1528
EPS:
-0.36
Flusso di cassa netto:
$-14.70M
1 W Prestazione:
+13.19%
1M Prestazione:
-15.76%
6M Prestazione:
+23.02%
1 anno Prestazione:
+9.15%
Intervallo 1D:
$0.68
$0.79
Intervallo di 1 settimana:
$0.646
$0.79
Portata 52W:
$0.3951
$0.94
VolitionRX Ltd Stock (VNRX) Company Profile
Nome
VolitionRX Ltd
Settore
Industria
Telefono
646 650 1351
Indirizzo
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Confronta VNRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.775 | 71.20M | 1.29M | -29.87M | -14.70M | -0.36 |
|
TMO
Thermo Fisher Scientific Inc
|
404.94 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
188.07 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.87 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.04 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.96 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-02-17 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-03-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-05-16 | Iniziato | Maxim Group | Buy |
| 2018-05-14 | Reiterato | The Benchmark Company | Buy |
| 2016-09-07 | Reiterato | Rodman & Renshaw | Buy |
| 2016-02-01 | Iniziato | Rodman & Renshaw | Buy |
Mostra tutto
VolitionRX Ltd Borsa (VNRX) Ultime notizie
Is VolitionRx Limited a good long term investmentSky-high profits - jammulinksnews.com
What drives VolitionRx Limited stock pricePowerful profit generation - jammulinksnews.com
Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation - MarketScreener
What makes VolitionRx Limited stock price move sharplyProven Win Setups - Newser
How VolitionRx Limited stock performs during market volatilityShort Term Risk Controlled Alerts - Newser
Why VolitionRx Limited stock attracts strong analyst attentionDefensive Stock Picks with Upside - Newser
VolitionRx Limited Announces Lateral Flow Test for Point-of-Care Quantification of Nucleosomes - MarketScreener
Breakthrough: New 5-Minute Blood Test Could Transform Emergency Care and Sepsis Detection - Stock Titan
Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes - Ariva
VolitionRx:Nu.Q advances in lung cancer management - Research Tree
VNRX INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of VolitionRx Ltd. (NYSE: VNRX) and Encourages Long-Term Investors to Contact the Firm - ACCESS Newswire
VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock By Investing.com - Investing.com India
VolitionRx CEO Cameron Reynolds acquires $7,372 in common stock - Investing.com
Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1 Concentrations Are Closely Associated With Sepsis And Organ Failure - MarketScreener
VolitionRx (NYSE:VNRX) Rating Increased to Strong-Buy at Jones Trading - Defense World
VolitionRX (VNRX) Coverage Initiated with a 'Buy' Rating by Jones Trading | VNRX Stock News - GuruFocus
JonesTrading Initiates Coverage on VolitionRx Limited With Buy Rating, $3 Price Target - marketscreener.com
Jones Trading initiates VolitionRX with Buy, sets $3 target By Investing.com - Investing.com India
VolitionRx (VNRX) Receives Buy Rating with Promising Price Targe - GuruFocus
VolitionRx initiated with a Buy at JonesResearch - TipRanks
VolitionRx (VNRX) Receives Buy Rating with Promising Price Target | VNRX Stock News - GuruFocus
Director Makes Bold Move with Major VolitionRX Stock Purchase - TipRanks
Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - Yahoo Finance
VolitionRx director Guy Innes buys $10,772 in common stock By Investing.com - Investing.com South Africa
VolitionRx director Guy Innes buys $10,772 in common stock - Investing.com
VNRX: Management's key financial goal for 2025 is to be cash neutral on a full year basis. - Research Tree
VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applicati - Yahoo Finance
VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript - Insider Monkey
VolitionRX Ltd. Earnings Call Reveals Promising Growth - TipRanks
VolitionRX shares hold as Benchmark maintains rating - Investing.com Australia
VNRX stock touches 52-week low at $0.42 amid market challenges - Investing.com Canada
VolitionRX shares hold as Benchmark maintains rating By Investing.com - Investing.com India
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - Yahoo Finance
VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats By Investing.com - Investing.com Canada
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones - Yahoo Finance
VolitionRx Reports Strong Q1 2025 Performance - TipRanks
VolitionRX (VNRX) Sees Revenue Growth and Cost Reduction in Q1 2 - GuruFocus
Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast By Investing.com - Investing.com Nigeria
Transcript : VolitionRx Limited, Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com
Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast - Investing.com
Volitionrx Ltd earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
VolitionRX: Q1 Earnings Snapshot - CT Insider
VolitionRx Q1 2025 Earnings Call Transcript - MarketBeat
Volitionrx Ltd earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa
VolitionRx reports Q1 revenue $0.25M, consensus $1.08M - TipRanks
Volition (VNRX) Targets Diagnostic Market Expansion with Nu.Q Platform | VNRX Stock News - GuruFocus
VolitionRX Ltd Reports Q1 2025 Revenue of $0.25 Million, Missing - GuruFocus
VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus
VolitionRX Ltd Azioni (VNRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.04%
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):